IQVIA Holdings (IQV) Stock Overview
Provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
IQV Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
IQVIA Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$171.99 |
| 52 Week High | US$247.05 |
| 52 Week Low | US$134.65 |
| Beta | 1.39 |
| 1 Month Change | 4.41% |
| 3 Month Change | -28.80% |
| 1 Year Change | 13.96% |
| 3 Year Change | -15.12% |
| 5 Year Change | -20.46% |
| Change since IPO | 308.43% |
Recent News & Updates
Recent updates
IQVIA Holdings Inc.'s (NYSE:IQV) P/E Still Appears To Be Reasonable
Jan 09
IQVIA: Increasingly Indispensable In Drug Development
Dec 11Earnings Tell The Story For IQVIA Holdings Inc. (NYSE:IQV) As Its Stock Soars 25%
Jul 24
At US$159, Is It Time To Put IQVIA Holdings Inc. (NYSE:IQV) On Your Watch List?
Jul 17We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Jun 29IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way
Feb 16IQVIA: Will This Beaten-Down Stock Bounce Back? 3 Things To Know
Dec 12Reiterating Buy On IQVIA After Q2 Earnings
Aug 20IQVIA: Long-Term Compounder Throwing Off Free Cash Flow
May 27IQVIA Holdings: Strong Q4 Results Suggest A Bullish 2024
Feb 22Shareholder Returns
| IQV | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.7% | 3.5% | 4.2% |
| 1Y | 14.0% | 9.2% | 29.0% |
Return vs Industry: IQV exceeded the US Life Sciences industry which returned 7.5% over the past year.
Return vs Market: IQV underperformed the US Market which returned 27.4% over the past year.
Price Volatility
| IQV volatility | |
|---|---|
| IQV Average Weekly Movement | 6.8% |
| Life Sciences Industry Average Movement | 7.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IQV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IQV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 93,000 | Ari Bousbib | www.iqvia.com |
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
IQVIA Holdings Inc. Fundamentals Summary
| IQV fundamental statistics | |
|---|---|
| Market cap | US$28.09b |
| Earnings (TTM) | US$1.36b |
| Revenue (TTM) | US$16.31b |
Is IQV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IQV income statement (TTM) | |
|---|---|
| Revenue | US$16.31b |
| Cost of Revenue | US$10.88b |
| Gross Profit | US$5.43b |
| Other Expenses | US$4.07b |
| Earnings | US$1.36b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.10 |
| Gross Margin | 33.29% |
| Net Profit Margin | 8.34% |
| Debt/Equity Ratio | 237.8% |
How did IQV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 05:33 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IQVIA Holdings Inc. is covered by 34 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Douglas Tsao | Barclays |